Column 1,Column 2,Column 3,Column 4,Column 5
Ingenuity Canonical Pathways, -log(p-value),Ratio,z-score,Molecules
Axonal Guidance Signaling,13.2,0.0542,#NUM!,"ADAMTS17,CXCL12,DPYSL5,ECEL1,EFNA5,GNAI1,ITGA7,ITGA8,MAG,MET,NFATC1,NRP1,NRP2,NTN1,PAK2,PAPPA,PFN2,PLXNB1,PRKAR2B,PRKD3,ROBO2,SEMA3G,SEMA4F,SLIT2,SRGAP1,TUBA4A,TUBB4A,WNT5A"
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by IGFBPs,6.62,0.0806,0,"CKAP4,FAM20C,IGFBP3,LTBP1,MATN3,PAPPA,PRSS23,QSOX1,TF,TIMP1"
Hepatic Fibrosis / Hepatic Stellate Cell Activation,6.61,0.0625,#NUM!,"A2M,ACTA2,COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,IFNAR1,IGFBP3,MET,TIMP1,TNFRSF1A"
Post-translational protein phosphorylation,6.17,0.0841,-0.333,"CKAP4,FAM20C,IGFBP3,LTBP1,MATN3,PRSS23,QSOX1,TF,TIMP1"
Semaphorin Signaling in Neurons,5.93,0.119,#NUM!,"DPYSL3,DPYSL5,MET,NRP1,PAK2,PLXNB1,RHOJ"
Semaphorin interactions,5.69,0.109,1.134,"DPYSL3,DPYSL5,HSP90AA1,MET,NRP1,PAK2,PLXNB1"
Osteoarthritis Pathway,5.63,0.0504,-1.265,"ALPL,CCN4,EPAS1,HTRA1,ITGA7,ITGA8,LEF1,MATN3,MEF2C,NAMPT,PPARD,TNFRSF1A"
EGR2 and SOX10-mediated initiation of Schwann cell myelination,5.2,0.172,-2.236,"DRP2,MAG,MPZ,PMP22,PRX"
Semaphorin Neuronal Repulsive Signaling Pathway,5.03,0.0612,-1.134,"DPYSL3,DPYSL5,ITGA7,ITGA8,NRP1,NRP2,PAK2,PLXNB1,PRKAR2B"
Assembly of collagen fibrils and other multimeric structures,4.68,0.0984,-1.633,"CD151,COL11A1,COL15A1,COL8A2,COL9A3,PXDN"
Hepatic Fibrosis Signaling Pathway,4.45,0.0337,-0.577,"ACTA2,FTH1,GNAI1,ITGA7,ITGA8,KLF9,LEF1,PRKAR2B,PRKD3,RHOJ,TF,TIMP1,TNFRSF1A,WNT5A"
Elastic fibre formation,4.29,0.114,-0.447,"EFEMP2,EMILIN1,ITGA8,LTBP1,MFAP5"
Collagen chain trimerization,4.29,0.114,-1.342,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3"
Extracellular matrix organization,4.21,0.0654,-0.378,"BGN,COL11A1,COL9A3,HAPLN1,ITGA7,ITGA8,MATN3"
Sphingolipid metabolism,4.13,0.0636,#NUM!,"ARSB,ARSG,CERS6,PRKD3,PSAP,SGPL1,ST3GAL5"
Signaling by ROBO receptors,3.99,0.0407,0,"CXCL12,MSI1,NRP1,NTN1,PAK2,PFN2,PSMD2,ROBO2,SLIT2,SRGAP1"
Sertoli Cell-Sertoli Cell Junction Signaling,3.98,0.0405,-0.707,"A2M,ACTA2,CDH13,CLDN19,GJA1,PAK2,TIMP1,TNFRSF1A,TUBA4A,TUBB4A"
Integrin Signaling,3.82,0.0429,-1.134,"ACTA2,ASAP1,ITGA7,ITGA8,PAK2,PFN2,RHOJ,TSPAN4,TSPAN5"
L1CAM interactions,3.81,0.0565,0.378,"CNTN6,NRP1,NRP2,NUMB,SCN7A,TUBA4A,TUBB4A"
Response to elevated platelet cytosolic Ca2+,3.64,0.053,-1.134,"A2M,CD9,PSAP,QSOX1,TF,TIMP1,TUBA4A"
Gap Junction Signaling,3.52,0.0328,0.632,"ACTA2,CCN3,GJA1,GNAI1,LEF1,P2RY2,PRKAR2B,PRKD3,TNFRSF1A,TUBA4A,TUBB4A"
Collagen biosynthesis and modifying enzymes,3.41,0.0746,-1.342,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3"
Regulation of Actin-based Motility by Rho,3.24,0.0541,0,"ACTA2,ITGA7,ITGA8,PAK2,PFN2,RHOJ"
O-linked glycosylation,3.2,0.0531,-1.633,"ADAMTS17,ADAMTSL1,ADAMTSL3,GCNT1,SBSPON,ST6GAL1"
Microautophagy Signaling Pathway,3.15,0.044,#NUM!,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,MAP1LC3A,PSMD2"
Signaling by Rho Family GTPases,3.06,0.0337,0.816,"ACTA2,CDH13,GNAI1,ITGA7,ITGA8,PAK2,RHOJ,SEPTIN4,SEPTIN5"
Pathogen Induced Cytokine Storm Signaling Pathway,3.05,0.0288,-2.111,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,CXCL12,CXCL14,FTH1,IFNAR1,RYR3,TNFRSF1A"
Formation of the ureteric bud,3.04,0.143,#NUM!,"ITGA8,ROBO2,SLIT2"
Pulmonary Fibrosis Idiopathic Signaling Pathway,3.03,0.0307,-1.265,"ACTA2,CCN4,COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,CXCL12,LEF1,WNT5A"
Germ Cell-Sertoli Cell Junction Signaling,2.97,0.0409,#NUM!,"A2M,ACTA2,PAK2,RHOJ,TNFRSF1A,TUBA4A,TUBB4A"
Glycosaminoglycan metabolism,2.91,0.0469,0,"ARSB,BGN,CHST2,HAS2,HS6ST1,HS6ST2"
ROBO SLIT Signaling Pathway,2.91,0.0469,0,"NTN1,PAK2,PRKAR2B,ROBO2,SLIT2,SRGAP1"
GP6 Signaling Pathway,2.91,0.0469,-0.816,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,PRKD3"
Netrin Signaling,2.91,0.04,-1.134,"DPYSL3,DPYSL5,NFATC1,NTN1,PRKAR2B,PRKD3,RYR3"
Leukocyte Extravasation Signaling,2.66,0.0361,-0.447,"ACTA2,CLDN19,CXCL12,GNAI1,PRKD3,SELPLG,TIMP1"
Collagen degradation,2.54,0.0625,-2,"COL11A1,COL15A1,COL8A2,COL9A3"
Hedgehog 'off' state,2.38,0.0439,#NUM!,"NUMB,PRKAR2B,PSMD2,TUBA4A,TUBB4A"
Remodeling of Epithelial Adherens Junctions,2.38,0.0563,#NUM!,"ACTA2,MET,TUBA4A,TUBB4A"
Cardiac Hypertrophy Signaling (Enhanced),2.36,0.0223,0,"GHR,GNAI1,IFNAR1,ITGA7,ITGA8,MEF2C,NFATC1,PRKAR2B,PRKD3,RYR3,TNFRSF1A,WNT5A"
RHOGDI Signaling,2.35,0.0318,0,"ACTA2,CDH13,GNAI1,ITGA7,ITGA8,PAK2,RHOJ"
Nuclear Cytoskeleton Signaling Pathway,2.34,0.0317,-1.633,"ACTA2,CDH13,ITGA7,ITGA8,KIF1A,TUBA4A,TUBB4A"
Xenobiotic Metabolism PXR Signaling Pathway,2.34,0.0317,-1.633,"ALDH1A1,CHST2,HS6ST1,HS6ST2,HSP90AA1,PRKAR2B,PRKD3"
Growth Hormone Signaling,2.33,0.0548,#NUM!,"A2M,GHR,IGFBP3,PRKD3"
Agranulocyte Adhesion and Diapedesis,2.31,0.0312,#NUM!,"ACTA2,CLDN19,CXCL12,CXCL14,GNAI1,SELPLG,TNFRSF1A"
Neutrophil degranulation,2.3,0.0231,-0.302,"ARSB,CKAP4,FTH1,HSP90AA1,MANBA,PGM1,PKP1,PSAP,PSMD2,QSOX1,RAB10"
Oxytocin Signaling Pathway,2.29,0.0281,0,"GJA1,GNAI1,MEF2C,NFATC1,PPARD,PRKAR2B,PRKD3,PTGFR"
RHOA Signaling,2.24,0.0407,0,"ACTA2,NRP2,PFN2,SEPTIN4,SEPTIN5"
Androgen Signaling,2.24,0.0343,#NUM!,"GNAI1,GTF2E1,HSP90AA1,PRKAR2B,PRKD3,TAF9B"
SUMOylation of immune response proteins,2.21,0.154,#NUM!,"EIF2AK2,SUMO3"
Cleavage and Polyadenylation of Pre-mRNA,2.21,0.154,#NUM!,"CPSF2,PAPOLA"
Mechanisms of Viral Exit from Host Cells,2.2,0.0732,#NUM!,"ACTA2,CHMP2B,PRKD3"
Tight Junction Signaling,2.17,0.0331,#NUM!,"ACTA2,CLDN19,CPSF2,PALS1,PRKAR2B,TNFRSF1A"
LXR/RXR Activation,2.14,0.0385,1.342,"APOD,PLTP,SERPINF1,TF,TNFRSF1A"
"Transport of vitamins, nucleosides, and related molecules",2.14,0.0698,#NUM!,"APOD,SLC35A2,SLCO3A1"
Cachexia Signaling Pathway,2.13,0.0245,1,"EIF2AK2,HSP90AA1,IGFBP3,LIFR,MEF2C,PRKAR2B,PRKD3,PSMD2,TNFRSF1A"
Aggrephagy,2.11,0.0682,#NUM!,"HSP90AA1,TUBA4A,TUBB4A"
Integrin cell surface interactions,2.1,0.0471,-2,"COL8A2,COL9A3,ITGA7,ITGA8"
Activation of NMDA receptors and postsynaptic events,2.1,0.0471,1,"PPM1F,PRKAR2B,TUBA4A,TUBB4A"
Response of EIF2AK1 (HRI) to heme deficiency,2.09,0.133,#NUM!,"ATF3,ATF5"
Carboxyterminal post-translational modifications of tubulin,2.08,0.0667,#NUM!,"TUBA4A,TUBB4A,VASH1"
Wound Healing Signaling Pathway,2.07,0.0281,-1.89,"ACTA2,COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,TNFRSF1A"
Role of PKR in Interferon Induction and Antiviral Response,2.04,0.0362,-0.447,"ATF3,EIF2AK2,HSP90AA1,IFNAR1,TNFRSF1A"
Role of Osteoclasts in Rheumatoid Arthritis Signaling Pathway,2.03,0.0252,-1.414,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,NFATC1,RHOJ,TNFRSF1A"
Tuberculosis Latent Signaling Pathway,2.01,0.0444,-1,"GNAI1,LRP2,PRKAR2B,TNFRSF1A"
Ephrin A Signaling,2.01,0.0357,-0.447,"EFNA5,EPAS1,NFATC1,PRKAR2B,SIPA1L1"
Cell junction organization,1.98,0.0435,-1,"CD151,CDH13,CLDN19,PALS1"
DHCR24 Signaling Pathway,1.98,0.035,1.342,"APOD,PLTP,PRKD3,SERPINF1,TF"
Pulmonary Healing Signaling Pathway,1.96,0.0299,0,"CXCL12,LEF1,NFATC1,PRKD3,TNFRSF1A,WNT5A"
Ephrin Receptor Signaling,1.95,0.0297,#NUM!,"CXCL12,EFNA5,GNAI1,ITGA7,ITGA8,PAK2"
Gap junction trafficking and regulation,1.94,0.0588,#NUM!,"GJA1,TUBA4A,TUBB4A"
Immunogenic Cell Death Signaling Pathway,1.93,0.0421,0,"HSP90AA1,IFNAR1,P2RY2,TNFRSF1A"
Granulocyte Adhesion and Diapedesis,1.93,0.0294,#NUM!,"CLDN19,CXCL12,CXCL14,GNAI1,SELPLG,TNFRSF1A"
Mitotic Prometaphase,1.92,0.0293,1.633,"CENPO,HSP90AA1,NEK9,PRKAR2B,TUBA4A,TUBB4A"
NAD Signaling Pathway,1.88,0.0331,0.447,"GJA1,NAMPT,PARP14,RYR3,TPCN1"
Colorectal Cancer Metastasis Signaling,1.88,0.0258,1.342,"GNAI1,LEF1,MSH2,PRKAR2B,RHOJ,TNFRSF1A,WNT5A"
Molecular Mechanisms of Cancer,1.85,0.0174,-0.775,"GHR,GNAI1,GPRC5A,GPRC5B,IFNAR1,ITGA7,ITGA8,LEF1,P2RY2,PAK2,PRKAR2B,PRKD3,PTGFR,RHOJ,WNT5A"
Receptor-type tyrosine-protein phosphatases,1.84,0.1,#NUM!,"PPFIA4,SLITRK6"
HSP90 chaperone cycle for steroid hormone receptors in the presence of ligand,1.8,0.0526,#NUM!,"HSP90AA1,TUBA4A,TUBB4A"
Eicosanoid Signaling,1.8,0.0248,-0.378,"GNAI1,LEF1,NFATC1,PPARD,PRKAR2B,PRKD3,PTGFR"
Ovarian Cancer Signaling,1.79,0.0314,#NUM!,"GJA1,LEF1,MSH2,PRKAR2B,WNT5A"
ERK/MAPK Signaling,1.78,0.0273,1,"ITGA7,ITGA8,NFATC1,PAK2,PPP1R14C,PRKAR2B"
Paxillin Signaling,1.77,0.0377,#NUM!,"ACTA2,ITGA7,ITGA8,PAK2"
Signaling by VEGF,1.76,0.0374,1,"HSP90AA1,NRP1,NRP2,PAK2"
Iron uptake and transport,1.75,0.05,#NUM!,"FTH1,SLC22A17,TF"
Dermatan Sulfate Biosynthesis (Late Stages),1.75,0.05,#NUM!,"CHST2,HS6ST1,HS6ST2"
"Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation",1.73,0.0492,#NUM!,"ARSB,ARSG,RIOX2"
Kinesins,1.71,0.0484,#NUM!,"KIF1A,TUBA4A,TUBB4A"
CXCR4 Signaling,1.7,0.0298,0.447,"CXCL12,GNAI1,PAK2,PRKD3,RHOJ"
Chondroitin Sulfate Biosynthesis (Late Stages),1.69,0.0476,#NUM!,"CHST2,HS6ST1,HS6ST2"
LPS/IL-1 Mediated Inhibition of RXR Function,1.68,0.0235,#NUM!,"ALDH1A1,CHST2,HS6ST1,HS6ST2,PLTP,SLC35A2,TNFRSF1A"
Xenobiotic Metabolism CAR Signaling Pathway,1.67,0.0258,-1.342,"ALDH1A1,CHST2,HS6ST1,HS6ST2,HSP90AA1,PRKD3"
Sertoli Cell-Germ Cell Junction Signaling Pathway (Enhanced),1.65,0.0254,0.447,"A2M,ACTA2,CLDN19,GJA1,PRKAR2B,TNFRSF1A"
Mitotic Metaphase and Anaphase,1.65,0.0254,1.633,"CENPO,CHMP2B,PSMD2,TUBA4A,TUBB4A,VRK1"
Pyridoxal 5'-phosphate Salvage Pathway,1.64,0.0455,#NUM!,"DYRK1A,EIF2AK2,PAK2"
Neuregulin Signaling,1.62,0.0339,#NUM!,"HSP90AA1,ITGA7,ITGA8,PRKD3"
RHO GTPase cycle,1.61,0.02,-0.333,"CKAP4,GJA1,HSP90AA1,PAK2,PLXNB1,RHOJ,SEMA4F,SRGAP1,STARD13"
Cardiogenesis,1.59,0.0741,#NUM!,"LEF1,MEF2C"
Pancreatic Secretion Signaling Pathway,1.59,0.0247,1.342,"Clca3b,PAK2,PRKAR2B,PRKD3,RYR3,STK39"
Chondroitin Sulfate Biosynthesis,1.55,0.0423,#NUM!,"CHST2,HS6ST1,HS6ST2"
Th1 Pathway,1.54,0.032,#NUM!,"ICOSLG,IFNAR1,NFATC1,RUNX3"
Translocation of SLC2A4 (GLUT4) to the plasma membrane,1.54,0.0417,#NUM!,"RAB10,TUBA4A,TUBB4A"
Processing of Capped Intronless Pre-mRNA,1.54,0.069,#NUM!,"CPSF2,PAPOLA"
Dermatan Sulfate Biosynthesis,1.52,0.0411,#NUM!,"CHST2,HS6ST1,HS6ST2"
Melatonin Signaling,1.51,0.0405,#NUM!,"GNAI1,PRKAR2B,PRKD3"
Neuroprotective Role of THOP1 in Alzheimer's Disease,1.49,0.0308,-2,"HTRA1,PRKAR2B,PRSS12,PRSS23"
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages,1.48,0.026,1.342,"APOD,PPP1R14C,PRKD3,RHOJ,TNFRSF1A"
Myelination Signaling Pathway,1.48,0.0213,0.378,"CNTN6,ID2,MAG,MPZ,NFATC1,PRKAR2B,WNT5A"
Nicotinate metabolism,1.48,0.0645,#NUM!,"NAMPT,PARP14"
Sonic Hedgehog Signaling,1.48,0.0645,#NUM!,"DYRK1A,PRKAR2B"
"Plasma lipoprotein assembly, remodeling, and clearance",1.48,0.0395,#NUM!,"A2M,PCSK5,PLTP"
HGF Signaling,1.48,0.0305,#NUM!,"ITGA7,ITGA8,MET,PRKD3"
14-3-3-mediated Signaling,1.47,0.0303,#NUM!,"PRKD3,TNFRSF1A,TUBA4A,TUBB4A"
RHO GTPases activate IQGAPs,1.46,0.0625,#NUM!,"TUBA4A,TUBB4A"
Surfactant metabolism,1.46,0.0625,#NUM!,"CKAP4,P2RY2"
VDR/RXR Activation,1.45,0.0385,#NUM!,"IGFBP3,PPARD,PRKD3"
PKR-mediated signaling,1.45,0.0385,#NUM!,"EIF2AK2,TUBA4A,TUBB4A"
Role of WNT/GSK-3β Signaling in the Pathogenesis of Influenza,1.45,0.0385,#NUM!,"IFNAR1,LEF1,WNT5A"
P2Y Purinergic Receptor Signaling Pathway,1.45,0.0299,1,"GNAI1,P2RY2,PRKAR2B,PRKD3"
NGF processing,1.44,0.25,#NUM!,PCSK5
Galactose catabolism,1.44,0.25,#NUM!,PGM1
Lysosomal oligosaccharide catabolism,1.44,0.25,#NUM!,MANBA
NAD Biosynthesis III,1.44,0.25,#NUM!,NAMPT
Neutrophil Extracellular Trap Signaling Pathway,1.44,0.0196,1.414,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,IFNAR1,PRKD3,SELPLG"
Caveolar-mediated Endocytosis Signaling,1.44,0.038,#NUM!,"ACTA2,ITGA7,ITGA8"
IL-7 Signaling Pathway,1.44,0.038,#NUM!,"EBF1,MET,NFATC1"
Sialic acid metabolism,1.43,0.0606,#NUM!,"ST3GAL5,ST6GAL1"
IL-17A Signaling in Fibroblasts,1.42,0.0375,#NUM!,"ACTA2,CXCL12,IGF2BP2"
Mitotic G2-G2/M phases,1.42,0.025,1.342,"HSP90AA1,PRKAR2B,PSMD2,TUBA4A,TUBB4A"
Human Embryonic Stem Cell Pluripotency,1.42,0.025,0.447,"HSP90AA1,ID2,LIFR,PRKD3,WNT5A"
PI3K/AKT Signaling,1.42,0.025,#NUM!,"GHR,HSP90AA1,IFNAR1,ITGA7,ITGA8"
Role of JAK family kinases in IL-6-type Cytokine Signaling,1.41,0.037,#NUM!,"HSP90AA1,LIFR,TIMP1"
RHO GTPases Activate Formins,1.39,0.0286,0,"CENPO,PFN2,TUBA4A,TUBB4A"
Cilium Assembly,1.39,0.0245,0.447,"ASAP1,HSP90AA1,PRKAR2B,TUBA4A,TUBB4A"
Sheddase Signaling Pathway,1.39,0.0245,-1.342,"CCN3,GNAI1,IGFBP3,MET,TIMP1"
Beta-catenin independent WNT signaling,1.38,0.0244,0,"LEF1,NFATC1,PSMD2,STK39,WNT5A"
Clathrin-mediated Endocytosis Signaling,1.35,0.0239,#NUM!,"ACTA2,APOD,MET,NUMB,TF"
VEGF Family Ligand-Receptor Interactions,1.34,0.0349,#NUM!,"NRP1,NRP2,PRKD3"
Opioid Signaling Pathway,1.33,0.0214,0,"GNAI1,LEF1,PRKAR2B,PRKD3,RYR3,SCN7A"
Endocannabinoid Cancer Inhibition Pathway,1.32,0.0272,-2,"ATF3,GNAI1,LEF1,PRKAR2B"
Inhibition of Matrix Metalloproteases,1.32,0.0526,#NUM!,"A2M,TIMP1"
Notch Signaling,1.32,0.0526,#NUM!,"MAG,NUMB"
ABRA Signaling Pathway,1.32,0.0341,#NUM!,"ACTA2,MEF2C,TAGLN"
RNA Polymerase II Transcription,1.3,0.0267,1,"CPSF2,GTF2E1,PAPOLA,TAF9B"
WNT/SHH Axonal Guidance Signaling Pathway,1.29,0.0265,-1,"LEF1,PRKAR2B,SEMA3G,WNT5A"
Factors Promoting Cardiogenesis in Vertebrates,1.29,0.0265,2,"LEF1,MEF2C,PRKD3,WNT5A"
Calcium Signaling,1.29,0.0229,0,"ACTA2,MEF2C,NFATC1,PRKAR2B,RYR3"
Actin Nucleation by ARP-WASP Complex,1.28,0.033,#NUM!,"ITGA7,ITGA8,RHOJ"
Lung Ionic Balance Signaling Pathway,1.27,0.0172,-1,"Clca3b,GPRC5A,GPRC5B,IFNAR1,P2RY2,PRKAR2B,PRKD3,PTGFR,TNFRSF1A"
Glycine Cleavage Complex,1.27,0.167,#NUM!,GLDC
Post-translational modification: synthesis of GPI-anchored proteins,1.26,0.0323,#NUM!,"ALPL,CPM,TEX101"
Corticotropin Releasing Hormone Signaling,1.26,0.0258,1,"GNAI1,MEF2C,PRKAR2B,PRKD3"
Heparan Sulfate Biosynthesis (Late Stages),1.25,0.0319,#NUM!,"CHST2,HS6ST1,HS6ST2"
Transcriptional regulation by RUNX3,1.23,0.0312,#NUM!,"LEF1,PSMD2,RUNX3"
Smooth Muscle Contraction,1.22,0.0465,#NUM!,"ACTA2,PAK2"
Death Receptor Signaling,1.22,0.0309,#NUM!,"ACTA2,PARP14,TNFRSF1A"
"Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis",1.21,0.0218,#NUM!,"ALPL,LEF1,NFATC1,TNFRSF1A,WNT5A"
Netrin-1 signaling,1.21,0.0455,#NUM!,"NTN1,SLIT2"
Assembly and cell surface presentation of NMDA receptors,1.21,0.0455,#NUM!,"TUBA4A,TUBB4A"
Fructose metabolism,1.2,0.143,#NUM!,ALDH1A1
Inhibition of ARE-Mediated mRNA Degradation Pathway,1.2,0.0247,#NUM!,"PAPOLA,PRKAR2B,PSMD2,TNFRSF1A"
Interleukin-10 signaling,1.19,0.0444,#NUM!,"TIMP1,TNFRSF1A"
Salvage Pathways of Pyrimidine Ribonucleotides,1.19,0.03,#NUM!,"DYRK1A,EIF2AK2,PAK2"
Heparan Sulfate Biosynthesis,1.18,0.0297,#NUM!,"CHST2,HS6ST1,HS6ST2"
Signaling by Retinoic Acid,1.17,0.0435,#NUM!,"ALDH1A1,PPARD"
GPER1 signaling,1.16,0.0291,#NUM!,"GNAI1,PRKAR2B,STK39"
Mouse Embryonic Stem Cell Pluripotency,1.16,0.0291,#NUM!,"ID2,LEF1,LIFR"
Gαq Signaling,1.15,0.0237,#NUM!,"GNAI1,NFATC1,PRKD3,RHOJ"
Cargo recognition for clathrin-mediated endocytosis,1.14,0.0286,#NUM!,"LRP2,TF,WNT5A"
IGF-1 Signaling,1.14,0.0286,#NUM!,"CCN3,IGFBP3,PRKAR2B"
Actin Cytoskeleton Signaling,1.13,0.0207,#NUM!,"ACTA2,ITGA7,ITGA8,PAK2,PFN2"
Protein Kinase A Signaling,1.13,0.0177,0,"GNAI1,LEF1,NFATC1,NTN1,PRKAR2B,PRKD3,RYR3"
WNT/β-catenin Signaling,1.12,0.0231,#NUM!,"GJA1,LEF1,PPARD,WNT5A"
MYC Mediated Apoptosis Signaling,1.11,0.04,#NUM!,"PRKAR2B,TNFRSF1A"
PPAR Signaling,1.11,0.0278,#NUM!,"HSP90AA1,PPARD,TNFRSF1A"
Serine biosynthesis,1.1,0.111,#NUM!,SERINC5
GDP-glucose Biosynthesis,1.1,0.111,#NUM!,PGM1
Th1 and Th2 Activation Pathway,1.1,0.0227,#NUM!,"ICOSLG,IFNAR1,NFATC1,RUNX3"
NR1H2 and NR1H3-mediated signaling,1.1,0.0392,#NUM!,"APOD,PLTP"
Assembly of RNA Polymerase II Complex,1.1,0.0392,#NUM!,"GTF2E1,TAF9B"
Apoptotic execution phase,1.08,0.0385,#NUM!,"PAK2,PKP1"
TNFR1 Signaling,1.08,0.0385,#NUM!,"PAK2,TNFRSF1A"
Amyloid Processing,1.08,0.0385,#NUM!,"BACE2,PRKAR2B"
α-Adrenergic Signaling,1.08,0.027,#NUM!,"GNAI1,PRKAR2B,PRKD3"
Regulation of Apoptosis,1.07,0.0377,#NUM!,"PAK2,PSMD2"
Xenobiotic Metabolism Signaling,1.06,0.0181,#NUM!,"ALDH1A1,CHST2,HS6ST1,HS6ST2,HSP90AA1,PRKD3"
Glucose and Glucose-1-phosphate Degradation,1.05,0.1,#NUM!,PGM1
Glycogen Degradation II,1.05,0.1,#NUM!,PGM1
Signaling by TGF-beta Receptor Complex,1.05,0.037,#NUM!,"ITGA8,LTBP1"
Sperm Motility,1.05,0.0195,#NUM!,"DYRK1A,GNAI1,MET,PRKAR2B,PRKD3"
Signaling by PTK6,1.04,0.0364,#NUM!,"EPAS1,GPNMB"
Somitogenesis,1.04,0.0364,#NUM!,"LEF1,PSMD2"
"Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis",1.03,0.0178,-0.816,"CXCL12,LEF1,NFATC1,PRKD3,TNFRSF1A,WNT5A"
Cholecystokinin/Gastrin-mediated Signaling,1.03,0.0256,#NUM!,"MEF2C,PRKD3,RHOJ"
PAK Signaling,1.02,0.0254,#NUM!,"ITGA7,ITGA8,PAK2"
Processing and activation of SUMO,1.01,0.0909,#NUM!,SUMO3
Pexophagy,1.01,0.0909,#NUM!,EPAS1
Ketolysis,1.01,0.0909,#NUM!,HADHB
Neurexins and neuroligins,1.01,0.0351,#NUM!,"LRRTM3,SIPA1L1"
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells,1.01,0.0252,#NUM!,"GNAI1,PRKAR2B,PRKD3"
Nitric Oxide Signaling in the Cardiovascular System,1,0.025,#NUM!,"HSP90AA1,PRKAR2B,PRKD3"
Acute Phase Response Signaling,0.997,0.0209,#NUM!,"A2M,SERPINF1,TF,TNFRSF1A"
Cellular Effects of Sildenafil (Viagra),0.987,0.0146,0.632,"ACTA2,GNAI1,GPRC5A,GPRC5B,HSP90AA1,MEF2C,NFATC1,P2RY2,PRKAR2B,PTGFR"
Renin-Angiotensin Signaling,0.987,0.0246,#NUM!,"PAK2,PRKAR2B,PRKD3"
GNRH Signaling,0.985,0.0207,1,"GNAI1,PAK2,PRKAR2B,PRKD3"
Regulation of the Epithelial-Mesenchymal Transition Pathway,0.979,0.0206,#NUM!,"ID2,LEF1,MET,WNT5A"
NRF2-mediated Oxidative Stress Response,0.978,0.0185,#NUM!,"ACTA2,FTH1,HSP90AA1,PRKD3,SLC35A2"
Vitamin D (calciferol) metabolism,0.978,0.0833,#NUM!,LRP2
Ketogenesis,0.978,0.0833,#NUM!,HADHB
Glycogen Degradation III,0.978,0.0833,#NUM!,PGM1
PCP (Planar Cell Polarity) Pathway,0.976,0.0333,#NUM!,"PFN2,WNT5A"
Retinoic acid Mediated Apoptosis Signaling,0.964,0.0328,#NUM!,"IFNAR1,PARP14"
Breast Cancer Regulation by Stathmin1,0.962,0.0149,-2.121,"GPRC5A,GPRC5B,P2RY2,PPP1R14C,PRKAR2B,PRKD3,PTGFR,TUBA4A,TUBB4A"
ILK Signaling,0.961,0.0203,0,"ACTA2,LEF1,RHOJ,TNFRSF1A"
PPARα/RXRα Activation,0.955,0.0202,1,"GHR,HSP90AA1,MEF2C,PRKAR2B"
TCF dependent signaling in response to WNT,0.955,0.0202,1,"LEF1,PSMD2,RUNX3,WNT5A"
Gαs Signaling,0.948,0.0236,#NUM!,"GNAI1,PRKAR2B,RYR3"
Transcriptional Regulation by MECP2,0.941,0.0317,#NUM!,"MEF2C,MET"
Insulin Secretion Signaling Pathway,0.934,0.0179,-0.447,"CPE,GHR,PRKAR2B,PRKD3,RYR3"
Clathrin-mediated endocytosis,0.933,0.0233,#NUM!,"LRP2,TF,WNT5A"
ID1 Signaling Pathway,0.932,0.0198,0,"ATF3,LIFR,PLXNB1,TNFRSF1A"
G Beta Gamma Signaling,0.926,0.0231,#NUM!,"GNAI1,PRKAR2B,PRKD3"
Chronic Myeloid Leukemia Signaling,0.925,0.0178,0.447,"HSP90AA1,LEF1,NFATC1,NUMB,WNT5A"
Intra-Golgi and retrograde Golgi-to-ER traffic,0.921,0.0196,-1,"KIF1A,MAN1A1,TUBA4A,TUBB4A"
SPINK1 Pancreatic Cancer Pathway,0.918,0.0308,#NUM!,"CPE,CPM"
Costimulation by the CD28 family,0.918,0.0229,#NUM!,"ICOSLG,PAK2,STK39"
Carnitine metabolism,0.915,0.0714,#NUM!,PPARD
Metabolism of nitric oxide: NOS3 activation and regulation,0.915,0.0714,#NUM!,HSP90AA1
Formation of axial mesoderm,0.915,0.0714,#NUM!,LEF1
Mitotic G1 phase and G1/S transition,0.911,0.0227,#NUM!,"DYRK1A,PSMD2,RRM2"
WNT/Ca+ pathway,0.908,0.0303,#NUM!,"NFATC1,WNT5A"
CLEAR Signaling Pathway,0.906,0.0175,1.342,"GHR,PRKD3,PSAP,TNFRSF1A,VPS8"
fMLP Signaling in Neutrophils,0.904,0.0226,#NUM!,"GNAI1,NFATC1,PRKD3"
IL-8 Signaling,0.898,0.0192,1,"GNAI1,PAK2,PRKD3,RHOJ"
Macroautophagy,0.897,0.0299,#NUM!,"CHMP2B,MAP1LC3A"
PXR/RXR Activation,0.897,0.0299,#NUM!,"ALDH1A1,PRKAR2B"
Role of PI3K/AKT Signaling in the Pathogenesis of Influenza,0.897,0.0299,#NUM!,"GNAI1,IFNAR1"
HIF1α Signaling,0.887,0.019,1,"HSP90AA1,MET,PRKD3,TF"
Agrin Interactions at Neuromuscular Junction,0.886,0.0294,#NUM!,"ACTA2,PAK2"
CCR3 Signaling in Eosinophils,0.883,0.0221,#NUM!,"GNAI1,PAK2,PRKD3"
Atherosclerosis Signaling,0.883,0.0221,#NUM!,"APOD,CXCL12,SELPLG"
RAC Signaling,0.876,0.0219,#NUM!,"ITGA7,ITGA8,PAK2"
Adipogenesis pathway,0.87,0.0217,#NUM!,"EBF1,TNFRSF1A,WNT5A"
Cell surface interactions at the vascular wall,0.866,0.0187,-2,"GRB14,GYPC,MAG,SELPLG"
Mismatch Repair,0.861,0.0625,#NUM!,MSH2
Mevalonate Pathway I,0.861,0.0625,#NUM!,HADHB
"D-myo-inositol (1,4,5)-trisphosphate Degradation",0.861,0.0625,#NUM!,INPP5A
Basal Cell Carcinoma Signaling,0.856,0.0282,#NUM!,"LEF1,WNT5A"
Glioma Invasiveness Signaling,0.856,0.0282,#NUM!,"RHOJ,TIMP1"
Signaling by NOTCH4,0.85,0.0213,#NUM!,"ACTA2,PSMD2,STK39"
Serotonin Receptor Signaling,0.839,0.0149,0.378,"CPE,GNAI1,PAK2,PRKAR2B,PRKD3,RHOJ,RYR3"
Ephrin B Signaling,0.837,0.0274,#NUM!,"CXCL12,GNAI1"
Prolactin receptor signaling,0.837,0.0588,#NUM!,GHR
Transcriptional regulation of pluripotent stem cells,0.837,0.0588,#NUM!,EPAS1
Germ layer formation at gastrulation,0.837,0.0588,#NUM!,LEF1
Chondroitin Sulfate Degradation (Metazoa),0.837,0.0588,#NUM!,ARSB
Glutaryl-CoA Degradation,0.837,0.0588,#NUM!,HADHB
1D-myo-inositol Hexakisphosphate Biosynthesis II (Mammalian),0.837,0.0588,#NUM!,INPP5A
"D-myo-inositol (1,3,4)-trisphosphate Biosynthesis",0.837,0.0588,#NUM!,INPP5A
MSP-RON Signaling in Cancer Cells Pathway,0.837,0.021,#NUM!,"ACTA2,LEF1,MET"
Hedgehog 'on' state,0.83,0.0208,#NUM!,"NUMB,PSMD2,STK39"
Bone Mineralization Signaling Pathway,0.83,0.0208,#NUM!,"ALPL,LEF1,WNT5A"
C-type lectin receptors (CLRs),0.824,0.0207,#NUM!,"NFATC1,PAK2,PSMD2"
Iron homeostasis signaling pathway,0.824,0.0207,#NUM!,"EPAS1,FTH1,TF"
Apelin Endothelial Signaling Pathway,0.824,0.0207,#NUM!,"GNAI1,MEF2C,PRKD3"
Extra-nuclear estrogen signaling,0.818,0.0267,#NUM!,"GNAI1,HSP90AA1"
Isoleucine Degradation I,0.814,0.0556,#NUM!,HADHB
Hepatic Cholestasis,0.811,0.0178,#NUM!,"ABCB4,PRKAR2B,PRKD3,TNFRSF1A"
Cellular response to hypoxia,0.809,0.0263,#NUM!,"EPAS1,PSMD2"
Interferon alpha/beta signaling,0.809,0.0263,#NUM!,"EIF2AK2,IFNAR1"
GPCR-Mediated Integration of Enteroendocrine Signaling Exemplified by an L Cell,0.809,0.0263,#NUM!,"GNAI1,PRKAR2B"
Macropinocytosis Signaling,0.809,0.0263,#NUM!,"MET,PRKD3"
Autism Signaling Pathway,0.802,0.0162,0,"ALDH1A1,LEF1,MET,PRKAR2B,WNT5A"
SUMOylation of DNA damage response and repair proteins,0.8,0.026,#NUM!,"SMC6,SUMO3"
Angiopoietin Signaling,0.8,0.026,#NUM!,"GRB14,PAK2"
Glyoxylate metabolism and glycine degradation,0.792,0.0526,#NUM!,GLDC
Mismatch Repair in Eukaryotes,0.792,0.0526,#NUM!,MSH2
Role of NFAT in Cardiac Hypertrophy,0.792,0.0175,2,"GNAI1,MEF2C,PRKAR2B,PRKD3"
NF-κB Activation by Viruses,0.792,0.0256,#NUM!,"EIF2AK2,PRKD3"
Renal Cell Carcinoma Signaling,0.792,0.0256,#NUM!,"MET,PAK2"
FAK Signaling,0.791,0.0125,-1.387,"ASAP1,EFNA5,GHR,GPRC5A,GPRC5B,IFNAR1,ITGA7,ITGA8,LEF1,MET,P2RY2,PAK2,PTGFR"
PTEN Signaling,0.787,0.0199,#NUM!,"GHR,ITGA7,ITGA8"
Signaling by MET,0.783,0.0253,#NUM!,"COL11A1,MET"
Parkinson's Signaling Pathway,0.775,0.0158,#NUM!,"ACTA2,ALDH1A1,SEPTIN5,TUBA4A,TUBB4A"
SUMOylation of transcription factors,0.772,0.05,#NUM!,SUMO3
Valine Degradation I,0.772,0.05,#NUM!,HADHB
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate),0.772,0.05,#NUM!,HADHB
Degradation of the extracellular matrix,0.766,0.0247,#NUM!,"A2M,HTRA1"
Chemokine Signaling,0.766,0.0247,#NUM!,"CXCL12,GNAI1"
RHO GTPases activate PAKs,0.753,0.0476,#NUM!,PAK2
EIF2 Signaling,0.751,0.0168,#NUM!,"ACTA2,ATF3,ATF5,EIF2AK2"
Epithelial Adherens Junction Signaling,0.747,0.019,#NUM!,"LEF1,MET,PAK2"
Role of Osteoblasts in Rheumatoid Arthritis Signaling Pathway,0.742,0.0167,-1,"ALPL,CXCL12,LEF1,WNT5A"
Superpathway of Inositol Phosphate Compounds,0.737,0.0166,#NUM!,"ALPL,INPP5A,PPFIA4,PPP1R14C"
Chaperone Mediated Autophagy,0.735,0.0455,#NUM!,HSP90AA1
Formation of paraxial mesoderm,0.735,0.0455,#NUM!,LEF1
"Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism",0.735,0.0455,#NUM!,INPP5A
Fatty Acid α-oxidation,0.735,0.0455,#NUM!,ALDH1A1
HEY1 Signaling Pathway,0.731,0.0186,#NUM!,"MEF2C,MFAP5,NFATC1"
eNOS Signaling,0.731,0.0186,#NUM!,"HSP90AA1,PRKAR2B,PRKD3"
BAG2 Signaling Pathway,0.726,0.0233,#NUM!,"HSP90AA1,PSMD2"
Regulation of the Epithelial Mesenchymal Transition in Development Pathway,0.726,0.0233,#NUM!,"LEF1,WNT5A"
Necroptosis Signaling Pathway,0.72,0.0184,#NUM!,"EIF2AK2,IFNAR1,TNFRSF1A"
Glucocorticoid Receptor Signaling,0.72,0.0133,#NUM!,"A2M,GHR,GJA1,GTF2E1,HSP90AA1,IFNAR1,NFATC1,TAF9B"
Histamine Degradation,0.717,0.0435,#NUM!,ALDH1A1
HOTAIR Regulatory Pathway,0.71,0.0182,#NUM!,"LEF1,MET,WNT5A"
Mitochondrial Division Signaling Pathway,0.704,0.0181,#NUM!,"MET,PRKAR2B,TNFRSF1A"
Coronavirus Replication Pathway,0.704,0.0181,#NUM!,"DDX1,TUBA4A,TUBB4A"
Regulation of mRNA stability by proteins that bind AU-rich elements,0.704,0.0225,#NUM!,"GPRC5A,PSMD2"
NAP1L1 Transcription Regulation Signaling Pathway,0.704,0.0225,#NUM!,"TUBA4A,TUBB4A"
Regulation of Cellular Mechanics by Calpain Protease,0.704,0.0225,#NUM!,"ITGA7,ITGA8"
Cyclophilin Signaling Pathway,0.703,0.0161,0,"CXCL12,LEF1,NFATC1,WNT5A"
Interleukin-6 family signaling,0.701,0.0417,#NUM!,LIFR
Role of Lipids/Lipid Rafts in the Pathogenesis of Influenza,0.701,0.0417,#NUM!,IFNAR1
Tryptophan Degradation III (Eukaryotic),0.701,0.0417,#NUM!,HADHB
Putrescine Degradation III,0.701,0.0417,#NUM!,ALDH1A1
Opioid Signalling,0.696,0.0222,#NUM!,"GNAI1,PRKAR2B"
Docosahexaenoic Acid (DHA) Signaling,0.695,0.0159,2,"PRKAR2B,PRKD3,SERPINF1,TNFRSF1A"
Degradation of beta-catenin by the destruction complex,0.689,0.022,#NUM!,"LEF1,PSMD2"
Insulin processing,0.685,0.04,#NUM!,CPE
Metabolism of cofactors,0.685,0.04,#NUM!,HSP90AA1
Glycogen metabolism,0.685,0.04,#NUM!,PGM1
Growth hormone receptor signaling,0.685,0.04,#NUM!,GHR
Mitochondrial RNA degradation,0.685,0.04,#NUM!,PNPT1
MAPK6/MAPK4 signaling,0.682,0.0217,#NUM!,"PAK2,PSMD2"
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza,0.682,0.0217,#NUM!,"EIF2AK2,IFNAR1"
Aldosterone Signaling in Epithelial Cells,0.679,0.0175,#NUM!,"HSP90AA1,HSPA12A,PRKD3"
Glioblastoma Multiforme Signaling,0.679,0.0175,#NUM!,"LEF1,RHOJ,WNT5A"
CREB Signaling in Neurons,0.679,0.013,-0.707,"GHR,GNAI1,GPRC5A,GPRC5B,P2RY2,PRKAR2B,PRKD3,PTGFR"
RAR Activation,0.676,0.0139,1.342,"ALDH1A1,IGFBP3,NFATC1,PPARD,PRKAR2B,RHOJ"
EPH-Ephrin signaling,0.675,0.0215,#NUM!,"EFNA5,PAK2"
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes,0.675,0.0215,#NUM!,"ACTA2,PRKD3"
ERBB Signaling,0.675,0.0215,#NUM!,"PAK2,PRKD3"
G-Protein Coupled Receptor Signaling,0.671,0.0126,-1,"GNAI1,GPRC5A,GPRC5B,MEF2C,NFATC1,P2RY2,PAK2,PRKAR2B,PTGFR"
Fertilization,0.67,0.0385,#NUM!,CD9
WNT ligand biogenesis and trafficking,0.67,0.0385,#NUM!,WNT5A
Cardiomyocyte Differentiation via BMP Receptors,0.67,0.0385,#NUM!,MEF2C
Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I,0.67,0.0385,#NUM!,RRM2
Ethanol Degradation IV,0.67,0.0385,#NUM!,ALDH1A1
Apelin Adipocyte Signaling Pathway,0.668,0.0213,#NUM!,"GNAI1,PRKAR2B"
Ribonucleotide Reductase Signaling Pathway,0.665,0.0172,#NUM!,"MET,PARP14,RRM2"
MITF-M-dependent gene expression,0.661,0.0211,#NUM!,"LEF1,MET"
Cardiac Hypertrophy Signaling,0.656,0.0153,2,"GNAI1,MEF2C,PRKAR2B,RHOJ"
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.655,0.037,#NUM!,NAMPT
ATF4 activates genes in response to endoplasmic reticulum stress,0.655,0.037,#NUM!,ATF3
Pyroptosis,0.655,0.037,#NUM!,CHMP2B
"Role of JAK1, JAK2 and TYK2 in Interferon Signaling",0.655,0.037,#NUM!,IFNAR1
Dopamine-DARPP32 Feedback in cAMP Signaling,0.646,0.0169,#NUM!,"GNAI1,PRKAR2B,PRKD3"
IL-1 Signaling,0.642,0.0204,#NUM!,"GNAI1,PRKAR2B"
Sulfur amino acid metabolism,0.641,0.0357,#NUM!,SQOR
CDP-diacylglycerol Biosynthesis I,0.641,0.0357,#NUM!,AGPAT5
Protein folding,0.635,0.0202,#NUM!,"TUBA4A,TUBB4A"
Protein Sorting Signaling Pathway,0.632,0.0166,#NUM!,"PRKAR2B,SNX4,SNX6"
Apelin Cardiomyocyte Signaling Pathway,0.629,0.02,#NUM!,"GNAI1,PRKD3"
SUMOylation of intracellular receptors,0.628,0.0345,#NUM!,SUMO3
Interconversion of nucleotide di- and triphosphates,0.628,0.0345,#NUM!,RRM2
Myogenesis,0.628,0.0345,#NUM!,MEF2C
TNFs bind their physiological receptors,0.628,0.0345,#NUM!,TNFRSF1A
Aryl Hydrocarbon Receptor Signaling,0.623,0.0164,#NUM!,"ALDH1A1,HSP90AA1,SLC35A2"
Ion channel transport,0.623,0.0164,#NUM!,"ANO5,RYR3,TPCN1"
Cellular response to heat stress,0.623,0.0198,#NUM!,"HSP90AA1,HSPA12A"
Neuropathic Pain Signaling in Dorsal Horn Neurons,0.623,0.0198,#NUM!,"PRKAR2B,PRKD3"
Sumoylation Pathway,0.623,0.0198,#NUM!,"RHOJ,SUMO3"
Circadian Rhythm Signaling,0.623,0.0148,#NUM!,"GNAI1,PRKAR2B,PRKD3,RYR3"
Pyroptosis Signaling Pathway,0.617,0.0196,#NUM!,"PRKAR2B,TNFRSF1A"
Gene Silencing by RNA,0.617,0.0196,#NUM!,"HSP90AA1,MYBL1"
COPI-mediated anterograde transport,0.617,0.0196,#NUM!,"TUBA4A,TUBB4A"
mRNA 3 Prime End Processing Signaling Pathway,0.617,0.0196,#NUM!,"CPSF2,PAPOLA"
"Tryptophan Degradation X (Mammalian, via Tryptamine)",0.615,0.0333,#NUM!,ALDH1A1
Phosphatidylglycerol Biosynthesis II (Non-plastidic),0.615,0.0333,#NUM!,AGPAT5
ABC-family proteins mediated transport,0.61,0.0194,#NUM!,"ABCB4,PSMD2"
MicroRNA Biogenesis Signaling Pathway,0.605,0.016,#NUM!,"DDX1,HSP90AA1,PNPT1"
Mitotic Prophase,0.604,0.0192,#NUM!,"NEK9,VRK1"
Endosomal Sorting Complex Required For Transport (ESCRT),0.603,0.0323,#NUM!,CHMP2B
Superpathway of Cholesterol Biosynthesis,0.603,0.0323,#NUM!,HADHB
"D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis",0.597,0.0159,#NUM!,"ALPL,PPFIA4,PPP1R14C"
"D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis",0.597,0.0159,#NUM!,"ALPL,PPFIA4,PPP1R14C"
RIPK1-mediated regulated necrosis,0.591,0.0312,#NUM!,HSP90AA1
WNK Renal Signaling Pathway,0.587,0.0187,#NUM!,"PRKD3,STK39"
Integration of energy metabolism,0.581,0.0185,#NUM!,"GNAI1,PRKAR2B"
Activation of Matrix Metalloproteinases,0.58,0.0303,#NUM!,TIMP1
Signal amplification,0.58,0.0303,#NUM!,GNAI1
MAPK targets/ Nuclear events mediated by MAP kinases,0.58,0.0303,#NUM!,MEF2C
Regulation of the Epithelial Mesenchymal Transition by Growth Factors Pathway,0.576,0.0155,#NUM!,"ID2,MET,TNFRSF1A"
ISGylation Signaling Pathway,0.576,0.0183,#NUM!,"EIF2AK2,IFNAR1"
Xenobiotic Metabolism AHR Signaling Pathway,0.576,0.0183,#NUM!,"ALDH1A1,HSP90AA1"
Transcriptional Regulation by E2F6,0.569,0.0294,#NUM!,RRM2
Late endosomal microautophagy,0.569,0.0294,#NUM!,CHMP2B
Methylglyoxal Degradation III,0.569,0.0294,#NUM!,DHRS1
Fatty Acid β-oxidation I,0.569,0.0294,#NUM!,HADHB
Interleukin-4 and Interleukin-13 signaling,0.565,0.018,#NUM!,"HSP90AA1,TIMP1"
Synaptic Long Term Depression,0.56,0.0152,#NUM!,"GNAI1,PRKD3,RYR3"
Acetylcholine Receptor Signaling Pathway,0.56,0.0152,#NUM!,"GNAI1,PRKAR2B,PRKD3"
Adrenergic Receptor Signaling Pathway (Enhanced),0.56,0.0152,#NUM!,"GNAI1,PRKAR2B,PRKD3"
Irritable Bowel Syndrome Signaling Pathway,0.558,0.0138,0,"DEFB116,RHOJ,TNFRSF1A,WNT5A"
Transcriptional Regulation by NPAS4,0.558,0.0286,#NUM!,NAMPT
Coagulation System,0.558,0.0286,#NUM!,A2M
3-phosphoinositide Degradation,0.552,0.015,#NUM!,"ALPL,PPFIA4,PPP1R14C"
Binding and Uptake of Ligands by Scavenger Receptors,0.549,0.0175,#NUM!,"FTH1,HSP90AA1"
Oxytocin in Brain Signaling Pathway,0.549,0.0149,#NUM!,"GNAI1,MEF2C,PRKD3"
Ethanol Degradation II,0.548,0.0278,#NUM!,ALDH1A1
TEC Kinase Signaling,0.545,0.0121,1,"ACTA2,GNAI1,ITGA7,ITGA8,PAK2,PRKD3,RHOJ"
Sleep NREM Signaling Pathway,0.538,0.0172,#NUM!,"GNAI1,PRKAR2B"
Prostate Cancer Signaling,0.538,0.0172,#NUM!,"HSP90AA1,LEF1"
Mitochondrial Fatty Acid Beta-Oxidation,0.538,0.027,#NUM!,HADHB
Gene and protein expression by JAK-STAT signaling after IL-12 stimulation,0.538,0.027,#NUM!,PAK2
Interferon Signaling,0.538,0.027,#NUM!,IFNAR1
D-myo-inositol-5-phosphate Metabolism,0.537,0.0147,#NUM!,"ALPL,PPFIA4,PPP1R14C"
Sirtuin Signaling Pathway,0.533,0.0135,#NUM!,"EPAS1,MAP1LC3A,NAMPT,TUBA4A"
Fc epsilon receptor (FCERI) signaling,0.53,0.0146,#NUM!,"NFATC1,PAK2,PSMD2"
S100 Family Signaling Pathway,0.529,0.0115,-0.333,"GPRC5A,GPRC5B,LEF1,P2RY2,PRKAR2B,PRKD3,PTGFR,SERPINF1,WNT5A"
ESR-mediated signaling,0.528,0.0169,#NUM!,"CXCL12,HSP90AA1"
Histone Modification Signaling Pathway,0.524,0.0133,0,"PPARD,RIOX2,SUMO3,VRK1"
Sphingosine-1-phosphate Signaling,0.523,0.0168,#NUM!,"GNAI1,RHOJ"
BBSome Signaling Pathway,0.519,0.0122,-1.633,"CXCL12,GPRC5A,GPRC5B,P2RY2,PRKAR2B,PTGFR"
Formation of Fibrin Clot (Clotting Cascade),0.518,0.0256,#NUM!,A2M
NGF-stimulated transcription,0.518,0.0256,#NUM!,ID2
Noradrenaline and Adrenaline Degradation,0.518,0.0256,#NUM!,ALDH1A1
Virus Entry via Endocytic Pathways,0.518,0.0167,#NUM!,"ACTA2,PRKD3"
Gustation Pathway,0.512,0.0142,#NUM!,"P2RY2,PRKAR2B,SCN7A"
Neurotransmitter release cycle,0.509,0.025,#NUM!,PPFIA4
Mitophagy,0.509,0.025,#NUM!,MAP1LC3A
Transcriptional Regulation by VENTX,0.509,0.025,#NUM!,LEF1
Dopamine Degradation,0.509,0.025,#NUM!,ALDH1A1
IL-15 Production,0.509,0.0164,#NUM!,"DYRK1A,MET"
Activin Inhibin Signaling Pathway,0.508,0.0142,#NUM!,"LEF1,NFATC1,TNFRSF1A"
Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency,0.504,0.0163,#NUM!,"LIFR,WNT5A"
DAG and IP3 signaling,0.5,0.0244,#NUM!,PRKAR2B
Acetone Degradation I (to Methylglyoxal),0.5,0.0244,#NUM!,DHRS1
Synaptic Long Term Potentiation,0.499,0.0161,#NUM!,"PRKAR2B,PRKD3"
p38 MAPK Signaling,0.499,0.0161,#NUM!,"MEF2C,TNFRSF1A"
3-phosphoinositide Biosynthesis,0.498,0.014,#NUM!,"ALPL,PPFIA4,PPP1R14C"
Asparagine N-linked glycosylation,0.495,0.016,#NUM!,"MAN1A1,ST6GAL1"
April Mediated Signaling,0.492,0.0238,#NUM!,NFATC1
TCR signaling,0.49,0.0159,#NUM!,"PAK2,PSMD2"
Phagosome Formation,0.487,0.0113,-1.414,"GPRC5A,GPRC5B,ITGA7,ITGA8,P2RY2,PAK2,PRKD3,PTGFR"
Multiple Sclerosis Signaling Pathway,0.484,0.0137,#NUM!,"PARP14,PPARD,TNFRSF1A"
Autophagy,0.484,0.0137,#NUM!,"MAP1LC3A,PRKAR2B,TNFRSF1A"
Vasopressin regulates renal water homeostasis via Aquaporins,0.484,0.0233,#NUM!,PRKAR2B
B Cell Activating Factor Signaling,0.484,0.0233,#NUM!,NFATC1
Oncostatin M Signaling,0.484,0.0233,#NUM!,EPAS1
Glycerophospholipid biosynthesis,0.481,0.0156,#NUM!,"AGPAT5,HADHB"
MHC class II antigen presentation,0.481,0.0156,#NUM!,"TUBA4A,TUBB4A"
Endocannabinoid Developing Neuron Pathway,0.481,0.0156,#NUM!,"GNAI1,PRKAR2B"
Synaptogenesis Signaling Pathway,0.478,0.0127,0,"CDH13,EFNA5,PRKAR2B,SNCG"
IL-6 Signaling,0.477,0.0155,#NUM!,"A2M,TNFRSF1A"
SUMOylation of transcription cofactors,0.475,0.0227,#NUM!,SUMO3
TP53 Regulates Transcription of Cell Death Genes,0.475,0.0227,#NUM!,IGFBP3
Retinoid metabolism and transport,0.475,0.0227,#NUM!,LRP2
Cardiac conduction,0.473,0.0154,#NUM!,"RYR3,SCN7A"
Thrombin Signaling,0.471,0.0135,#NUM!,"GNAI1,PRKD3,RHOJ"
TR/RXR Activation,0.468,0.0153,#NUM!,"KLF9,PPARD"
Defensins,0.468,0.0222,#NUM!,DEFB116
SUMOylation of DNA replication proteins,0.46,0.0217,#NUM!,SUMO3
Apelin Pancreas Signaling Pathway,0.46,0.0217,#NUM!,PRKAR2B
IL-27 Signaling Pathway,0.456,0.0149,#NUM!,"IFNAR1,TNFRSF1A"
Gα12/13 Signaling,0.456,0.0149,#NUM!,"CDH13,MEF2C"
Heme signaling,0.452,0.0213,#NUM!,MEF2C
Glutaminergic Receptor Signaling Pathway (Enhanced),0.452,0.0123,0,"GNAI1,PRKAR2B,PRKD3,SCN7A"
G alpha (z) signalling events,0.445,0.0208,#NUM!,GNAI1
Inositol phosphate metabolism,0.445,0.0208,#NUM!,INPP5A
Ferroptosis Signaling Pathway,0.443,0.0146,#NUM!,"FTH1,TF"
Neurovascular Coupling Signaling Pathway,0.443,0.0129,#NUM!,"GJA1,PRKAR2B,RYR3"
Neuroinflammation Signaling Pathway,0.442,0.0121,0,"BACE2,CXCL12,NFATC1,TNFRSF1A"
SNARE Signaling Pathway,0.439,0.0145,#NUM!,"PRKAR2B,SNCG"
CGAS-STING Signaling Pathway,0.439,0.0145,#NUM!,"GJA1,MAP1LC3A"
Nucleosome assembly,0.438,0.0204,#NUM!,CENPO
Apelin Muscle Signaling Pathway,0.438,0.0204,#NUM!,GNAI1
PFKFB4 Signaling Pathway,0.438,0.0204,#NUM!,PRKAR2B
Class A/1 (Rhodopsin-like receptors),0.437,0.012,-2,"CXCL12,P2RY2,PSAP,PTGFR"
STAT3 Pathway,0.436,0.0144,#NUM!,"GHR,IFNAR1"
GABAergic Receptor Signaling Pathway (Enhanced),0.432,0.0143,#NUM!,"GNAI1,PRKAR2B"
Signaling by ERBB2,0.431,0.02,#NUM!,HSP90AA1
Signaling by TGFBR3,0.431,0.02,#NUM!,TIMP1
nNOS Signaling in Neurons,0.431,0.02,#NUM!,PRKD3
nNOS Signaling in Skeletal Muscle Cells,0.431,0.02,#NUM!,RYR3
Retinoate Biosynthesis I,0.431,0.02,#NUM!,ALDH1A1
Th2 Pathway,0.428,0.0142,#NUM!,"ICOSLG,RUNX3"
Transcriptional regulation of granulopoiesis,0.424,0.0196,#NUM!,LEF1
Transcriptional and post-translational regulation of MITF-M expression and activity,0.424,0.0196,#NUM!,LEF1
UVC-Induced MAPK Signaling,0.424,0.0196,#NUM!,PRKD3
FAT10 Cancer Signaling Pathway,0.424,0.0196,#NUM!,TNFRSF1A
Role of Chondrocytes in Rheumatoid Arthritis Signaling Pathway,0.416,0.0139,#NUM!,"CXCL12,TNFRSF1A"
IL-12 Signaling and Production in Macrophages,0.414,0.0124,#NUM!,"APOD,NFATC1,PRKD3"
AMPK Signaling,0.408,0.0123,#NUM!,"GNAI1,PPM1F,PRKAR2B"
Gαi Signaling,0.406,0.0136,#NUM!,"GNAI1,PRKAR2B"
UVB-Induced MAPK Signaling,0.405,0.0185,#NUM!,PRKD3
Neddylation,0.403,0.0122,#NUM!,"EPAS1,FBXO11,PSMD2"
Intrinsic Pathway for Apoptosis,0.399,0.0182,#NUM!,SEPTIN4
Endocannabinoid Neuronal Synapse Pathway,0.395,0.0133,#NUM!,"GNAI1,PRKAR2B"
E3 ubiquitin ligases ubiquitinate target proteins,0.393,0.0179,#NUM!,RNF144A
CNTF Signaling,0.393,0.0179,#NUM!,LIFR
Phototransduction Pathway,0.393,0.0179,#NUM!,PRKAR2B
FAT10 Signaling Pathway,0.393,0.0179,#NUM!,PSMD2
Dilated Cardiomyopathy Signaling Pathway,0.392,0.0132,#NUM!,"ACTA2,PRKAR2B"
Transcriptional regulation by RUNX1,0.388,0.0132,#NUM!,"LIFR,PSMD2"
KEAP1-NFE2L2 pathway,0.388,0.0132,#NUM!,"PSMD2,STK39"
Type II Diabetes Mellitus Signaling,0.388,0.0132,#NUM!,"PRKD3,TNFRSF1A"
TNF signaling,0.387,0.0175,#NUM!,TNFRSF1A
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses,0.381,0.013,#NUM!,"EIF2AK2,PRKD3"
Circadian Clock,0.381,0.0172,#NUM!,MEF2C
Signaling by PDGF,0.381,0.0172,#NUM!,COL9A3
Triacylglycerol Biosynthesis,0.381,0.0172,#NUM!,AGPAT5
Signaling by ERBB4,0.376,0.0169,#NUM!,CXCL12
Metabolism of polyamines,0.376,0.0169,#NUM!,PSMD2
Relaxin Signaling,0.375,0.0128,#NUM!,"GNAI1,PRKAR2B"
G alpha (i) signalling events,0.372,0.0116,#NUM!,"CXCL12,GNAI1,PSAP"
NIK-->noncanonical NF-kB signaling,0.37,0.0167,#NUM!,PSMD2
GABA receptor activation,0.37,0.0167,#NUM!,GNAI1
Endometrial Cancer Signaling,0.37,0.0167,#NUM!,LEF1
Hematoma Resolution Signaling Pathway,0.369,0.0116,#NUM!,"FTH1,SQOR,TUBA4A"
p75 NTR receptor-mediated signalling,0.368,0.0127,#NUM!,"MAG,STK39"
HMGB1 Signaling,0.362,0.0125,#NUM!,"RHOJ,TNFRSF1A"
IL-4 Signaling,0.36,0.0104,-1.633,"COL11A1,COL15A1,COL20A1,COL8A2,COL9A3,GNAI1"
MSP-RON Signaling Pathway,0.36,0.0161,#NUM!,ACTA2
Preeclampsia Signaling Pathway,0.359,0.0124,#NUM!,"LIFR,TIMP1"
NCAM signaling for neurite out-growth,0.354,0.0159,#NUM!,COL9A3
Stearate Biosynthesis I (Animals),0.354,0.0159,#NUM!,DHRS1
Transcriptional Regulatory Network in Embryonic Stem Cells,0.35,0.0122,#NUM!,"LIFR,WNT5A"
Mitochondrial biogenesis,0.349,0.0156,#NUM!,MEF2C
Thrombopoietin Signaling,0.349,0.0156,#NUM!,PRKD3
Hedgehog ligand biogenesis,0.345,0.0154,#NUM!,PSMD2
RAB geranylgeranylation,0.345,0.0154,#NUM!,RAB10
Role of JAK2 in Hormone-like Cytokine Signaling,0.345,0.0154,#NUM!,GHR
Activation of IRF by Cytosolic Pattern Recognition Receptors,0.34,0.0152,#NUM!,IFNAR1
Induction of Apoptosis by HIV1,0.34,0.0152,#NUM!,TNFRSF1A
Oxidative Ethanol Degradation III,0.34,0.0152,#NUM!,ALDH1A1
Abacavir ADME,0.335,0.0149,#NUM!,STK39
Ribavirin ADME,0.335,0.0149,#NUM!,STK39
Mitotic Roles of Polo-Like Kinase,0.335,0.0149,#NUM!,HSP90AA1
ERBB4 Signaling,0.335,0.0149,#NUM!,PRKD3
Signaling by the B Cell Receptor (BCR),0.332,0.0118,#NUM!,"NFATC1,PSMD2"
Cardiac β-adrenergic Signaling,0.332,0.0118,#NUM!,"GNAI1,PRKAR2B"
TNFR2 non-canonical NF-kB pathway,0.33,0.0147,#NUM!,PSMD2
Phagosome Maturation,0.329,0.0117,#NUM!,"TUBA4A,TUBB4A"
Protein Ubiquitination Pathway,0.323,0.0108,#NUM!,"HSP90AA1,HSPA12A,PSMD2"
TP53 Regulates Transcription of DNA Repair Genes,0.321,0.0143,#NUM!,MSH2
G alpha (q) signalling events,0.321,0.0115,#NUM!,"P2RY2,PTGFR"
SUMOylation of chromatin organization proteins,0.317,0.0141,#NUM!,SUMO3
Regulation of RUNX2 expression and activity,0.313,0.0139,#NUM!,PSMD2
Dopamine Receptor Signaling,0.313,0.0139,#NUM!,PRKAR2B
Huntington's Disease Signaling,0.306,0.0105,#NUM!,"PRKD3,PSMD2,TAF9B"
Tumor Microenvironment Pathway,0.305,0.0111,#NUM!,"CXCL12,TNFRSF1A"
ISG15 antiviral mechanism,0.304,0.0135,#NUM!,EIF2AK2
ERK5 Signaling,0.304,0.0135,#NUM!,MEF2C
trans-Golgi Network Vesicle Budding,0.3,0.0133,#NUM!,FTH1
Pre-NOTCH Expression and Processing,0.292,0.013,#NUM!,POGLUT1
Signaling by NOTCH1,0.292,0.013,#NUM!,NUMB
Leptin Signaling in Obesity,0.292,0.013,#NUM!,PRKAR2B
Toll-like Receptor Signaling,0.292,0.013,#NUM!,EIF2AK2
Maturity Onset Diabetes of Young (MODY) Signaling,0.289,0.0128,#NUM!,APOD
Thyroid Cancer Signaling,0.289,0.0128,#NUM!,LEF1
Hypoxia Signaling in the Cardiovascular System,0.289,0.0128,#NUM!,HSP90AA1
Macrophage Classical Activation Signaling Pathway,0.285,0.0106,#NUM!,"IFNAR1,PARP14"
Hepatitis B Chronic Liver Pathogenesis Signaling Pathway,0.285,0.0106,#NUM!,"IFNAR1,PRKD3"
Regulation of eIF4 and p70S6K Signaling,0.285,0.0106,#NUM!,"ITGA7,ITGA8"
Role of MAPK Signaling in Inhibiting the Pathogenesis of Influenza,0.285,0.0127,#NUM!,EIF2AK2
IL-17 Signaling,0.283,0.0106,#NUM!,"DEFB116,HSP90AA1"
G alpha (12/13) signalling events,0.281,0.0125,#NUM!,PLXNB1
Role of BRCA1 in DNA Damage Response,0.281,0.0125,#NUM!,MSH2
Estrogen Receptor Signaling,0.279,0.00973,#NUM!,"GNAI1,HSP90AA1,PRKAR2B,PRKD3"
DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.277,0.0123,#NUM!,HSP90AA1
Signaling by NTRK1 (TRKA),0.277,0.0123,#NUM!,MEF2C
IL-3 Signaling,0.277,0.0123,#NUM!,PRKD3
Macrophage Alternative Activation Signaling Pathway,0.276,0.0104,#NUM!,"EPAS1,PPARD"
Metabolism of water-soluble vitamins and cofactors,0.274,0.0122,#NUM!,LRP2
BEX2 Signaling Pathway,0.274,0.0122,#NUM!,LEF1
NOD1/2 Signaling Pathway,0.274,0.0104,#NUM!,"HSP90AA1,IFNAR1"
Endothelin-1 Signaling,0.272,0.0103,#NUM!,"GNAI1,PRKD3"
RNA polymerase II transcribes snRNA genes,0.27,0.012,#NUM!,GTF2E1
IL-33 Signaling Pathway,0.269,0.0103,#NUM!,"NFATC1,PRKAR2B"
FXR/RXR Activation,0.269,0.0103,#NUM!,"ABCB4,PLTP"
Transcriptional regulation of white adipocyte differentiation,0.267,0.0119,#NUM!,EBF1
PEDF Signaling,0.267,0.0119,#NUM!,SERPINF1
CDX Gastrointestinal Cancer Signaling Pathway,0.265,0.0102,#NUM!,"LEF1,WNT5A"
LPS-stimulated MAPK Signaling,0.264,0.0118,#NUM!,PRKD3
FGF Signaling,0.26,0.0116,#NUM!,MET
PDGF Signaling,0.257,0.0115,#NUM!,EIF2AK2
Oxidative Stress Induced Senescence,0.254,0.0114,#NUM!,TNIK
Regulation of mitotic cell cycle,0.254,0.0114,#NUM!,PSMD2
Amyloid fiber formation,0.254,0.0114,#NUM!,TSPAN5
Natural Killer Cell Signaling,0.252,0.00985,#NUM!,"NFATC1,PAK2"
RAB GEFs exchange GTP for GDP on RABs,0.247,0.0111,#NUM!,RAB10
BMP signaling pathway,0.247,0.0111,#NUM!,PRKAR2B
Ceramide Signaling,0.244,0.011,#NUM!,TNFRSF1A
Role of Tissue Factor in Cancer,0.242,0.00962,#NUM!,"MET,TNFRSF1A"
Acute Myeloid Leukemia Signaling,0.241,0.0109,#NUM!,LEF1
Regulation of TP53 Activity through Phosphorylation,0.238,0.0108,#NUM!,TAF9B
Factors involved in megakaryocyte development and platelet production,0.238,0.0108,#NUM!,PRKAR2B
RANK Signaling in Osteoclasts,0.238,0.0108,#NUM!,NFATC1
Class B/2 (Secretin family receptors),0.233,0.0105,#NUM!,WNT5A
Serotonin Degradation,0.233,0.0105,#NUM!,ALDH1A1
mTOR Signaling,0.23,0.00935,#NUM!,"PRKD3,RHOJ"
Prolactin Signaling,0.23,0.0104,#NUM!,PRKD3
TGF-β Signaling,0.227,0.0103,#NUM!,RUNX3
VEGF Signaling,0.227,0.0103,#NUM!,ACTA2
Interferon gamma signaling,0.224,0.0102,#NUM!,TRIM35
Crosstalk between Dendritic Cells and Natural Killer Cells,0.224,0.0102,#NUM!,ACTA2
UVA-Induced MAPK Signaling,0.224,0.0102,#NUM!,PARP14
Melanocyte Development and Pigmentation Signaling,0.221,0.0101,#NUM!,PRKAR2B
S Phase,0.219,0.01,#NUM!,PSMD2
Response of EIF2AK4 (GCN2) to amino acid deficiency,0.211,0.00971,#NUM!,ATF3
Kinetochore Metaphase Signaling Pathway,0.211,0.00971,#NUM!,CENPO
DNA Replication Pre-Initiation,0.209,0.00962,#NUM!,PSMD2
Sleep REM Signaling Pathway,0.204,0.00943,#NUM!,PRKAR2B
CDK5 Signaling,0.204,0.00943,#NUM!,PRKAR2B
Apoptosis Signaling,0.204,0.00943,#NUM!,TNFRSF1A
Transport of inorganic cations/anions and amino acids/oligopeptides,0.199,0.00926,#NUM!,SLC9A9
Telomerase Signaling,0.199,0.00926,#NUM!,HSP90AA1
IL-13 Signaling Pathway,0,0.00813,#NUM!,DEFB116
IL-10 Signaling,0,0.00645,#NUM!,CCN4
Fc Epsilon RI Signaling,0,0.00833,#NUM!,PRKD3
Chaperone Mediated Autophagy Signaling Pathway,0,0.00157,#NUM!,HSP90AA1
NFKBIE Signaling Pathway,0,0.00223,#NUM!,TNFRSF1A
Orexin Signaling Pathway,0,0.00826,#NUM!,"PRKAR2B,PRKD3"
PIP3 activates AKT signaling,0,0.0069,#NUM!,MET
Fcgamma receptor (FCGR) dependent phagocytosis,0,0.0061,#NUM!,HSP90AA1
Generic Transcription Pathway,0,0.00466,#NUM!,"NRBP1,PPARD"
Phase I - Functionalization of compounds,0,0.00885,#NUM!,ALDH1A1
Regulation of lipid metabolism by PPARalpha,0,0.0084,#NUM!,ABCB4
G alpha (s) signalling events,0,0.0069,#NUM!,GNAI1
Interleukin-1 family signaling,0,0.00775,#NUM!,PSMD2
RAF/MAP kinase cascade,0,0.00763,#NUM!,"MET,PSMD2"
Deubiquitination,0,0.00755,#NUM!,"PSMD2,TAF9B"
Nucleotide Excision Repair,0,0.00917,#NUM!,SUMO3
Keratinization,0,0.00463,#NUM!,PKP1
PTEN Regulation,0,0.00667,#NUM!,PSMD2
Synthesis of DNA,0,0.0082,#NUM!,PSMD2
Cell Cycle Checkpoints,0,0.00735,#NUM!,"CENPO,PSMD2"
Processing of Capped Intron-Containing Pre-mRNA,0,0.00694,#NUM!,"CPSF2,PAPOLA"
Expression and translocation of olfactory receptors,0,0.00246,#NUM!,EBF1
Class I MHC mediated antigen processing and presentation,0,0.00525,#NUM!,"FBXO11,PSMD2"
Mitochondrial Dysfunction,0,0.0058,#NUM!,"BACE2,PRKAR2B"
NAFLD Signaling Pathway,0,0.00446,#NUM!,TNFRSF1A
Glycation Signaling Pathway,0,0.00444,#NUM!,PRKD3
Ribosomal Quality Control Signaling Pathway,0,0.00379,#NUM!,PSMD2
Chromatin organization,0,0.00392,#NUM!,RIOX2
TRIM21 Intracellular Antibody Signaling Pathway,0,0.00529,#NUM!,"IFNAR1,MAP1LC3A,PSMD2"
Cerebral Malformation Signaling Pathway,0,0.00855,#NUM!,MEF2C
ID3 Signaling Pathway,0,0.00103,#NUM!,ALPL
Tuberculosis Active Signaling Pathway,0,0.00408,#NUM!,TNFRSF1A
Erythropoietin Signaling Pathway,0,0.00552,#NUM!,PRKD3
Role of NFAT in Regulation of the Immune Response,0,0.00287,#NUM!,"GNAI1,MEF2C,NFATC1"
CCR5 Signaling in Macrophages,0,0.00399,#NUM!,"GNAI1,PRKD3"
Calcium-induced T Lymphocyte Apoptosis,0,0.00215,#NUM!,PRKD3
Airway Pathology in Chronic Obstructive Pulmonary Disease,0,0.00877,#NUM!,APOD
CTLA4 Signaling in Cytotoxic T Lymphocytes,0,0.00164,#NUM!,NFATC1
T Helper Cell Differentiation,0,0.00422,#NUM!,"ICOSLG,TNFRSF1A"
CD28 Signaling in T Helper Cells,0,0.00192,#NUM!,NFATC1
Dendritic Cell Maturation,0,0.00329,#NUM!,"IFNAR1,TNFRSF1A"
ICOS-ICOSL Signaling in T Helper Cells,0,0.00391,#NUM!,"ICOSLG,NFATC1"
Lipid Antigen Presentation by CD1,0,0.00242,#NUM!,PSAP
Type I Diabetes Mellitus Signaling,0,0.00391,#NUM!,"CPE,TNFRSF1A"
Glioma Signaling,0,0.00781,#NUM!,PRKD3
p70S6K Signaling,0,0.00344,#NUM!,"GNAI1,PRKD3"
G Protein Signaling Mediated by Tubby,0,0.00426,#NUM!,"GNAI1,NAMPT"
Systemic Lupus Erythematosus Signaling,0,0.000936,#NUM!,NFATC1
CDC42 Signaling,0,0.00519,#NUM!,"ITGA7,ITGA8,PAK2"
Hereditary Breast Cancer Signaling,0,0.00725,#NUM!,MSH2
Phospholipase C Signaling,0,0.00534,1,"ITGA7,ITGA8,MEF2C,NFATC1,PRKD3,RHOJ"
HER-2 Signaling in Breast Cancer,0,0.00441,#NUM!,PRKD3
Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes,0,0.00214,#NUM!,NFATC1
NUR77 Signaling in T Lymphocytes,0,0.00385,#NUM!,"NFATC1,PRKD3"
PKCθ Signaling in T Lymphocytes,0,0.00179,#NUM!,NFATC1
PI3K Signaling in B Lymphocytes,0,0.00507,#NUM!,"ATF3,ATF5,NFATC1"
SAPK/JNK Signaling,0,0.00199,#NUM!,NFATC1
GABA Receptor Signaling,0,0.00752,#NUM!,GNAI1
B Cell Receptor Signaling,0,0.0047,#NUM!,"EBF1,MEF2C,NFATC1"
Insulin Receptor Signaling,0,0.00775,#NUM!,PRKAR2B
cAMP-mediated signaling,0,0.0083,#NUM!,"GNAI1,PRKAR2B"
NF-κB Signaling,0,0.00525,#NUM!,"EIF2AK2,GHR,TNFRSF1A"
T Cell Receptor Signaling,0,0.00482,#NUM!,"ICOSLG,LEF1,NFATC1"
"PD-1, PD-L1 cancer immunotherapy pathway",0,0.00877,#NUM!,TNFRSF1A
Adrenomedullin signaling pathway,0,0.00495,#NUM!,PRKAR2B
Th17 Activation Pathway,0,0.00612,#NUM!,"DEFB116,HSP90AA1,NFATC1"
T Cell Exhaustion Signaling Pathway,0,0.00353,#NUM!,"IFNAR1,NFATC1"
Systemic Lupus Erythematosus in T Cell Signaling Pathway,0,0.0062,#NUM!,"GNAI1,ICOSLG,RHOJ,SELPLG"
Systemic Lupus Erythematosus in B Cell Signaling Pathway,0,0.00412,#NUM!,"IFNAR1,NFATC1,PRKD3"
Senescence Pathway,0,0.00664,#NUM!,"ATF3,NFATC1"
White Adipose Tissue Browning Pathway,0,0.00719,#NUM!,PRKAR2B
Xenobiotic Metabolism General Signaling Pathway,0,0.00613,#NUM!,PRKD3
Coronavirus Pathogenesis Pathway,0,0.00474,#NUM!,IFNAR1